Comparative Pharmacology
Head-to-head clinical analysis: NORQUEST FE versus OVULEN 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORQUEST FE versus OVULEN 21.
NORQUEST FE vs OVULEN-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
None Documented
None Documented
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant.
Category C
Category C
Oral Contraceptive
Oral Contraceptive